Firebrick Pharma Limited (FRE.AX)
AUD 0.07
(0.0%)
AUD 0.07
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 | 14.52 Thousand AUD | 1649.64% |
| 2023 | 830.00 AUD | -79.87% |
| 2022 | 4124.00 AUD | -99.02% |
| 2021 | 422 Thousand AUD | -17.09% |
| 2020 | 508.97 Thousand AUD | 0.0% |
| 2019 | - AUD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 FY | 14.52 Thousand AUD | 1649.64% |
| 2024 Q4 | 467.08 Thousand AUD | 0.0% |
| 2024 Q1 | 908.06 Thousand AUD | 0.0% |
| 2024 Q2 | 908.06 Thousand AUD | 0.0% |
| 2024 Q3 | 467.08 Thousand AUD | -48.56% |
| 2023 Q1 | 11.27 Thousand AUD | 1399.34% |
| 2023 FY | 830.00 AUD | -79.87% |
| 2023 Q4 | - AUD | 0.0% |
| 2023 Q3 | - AUD | -100.0% |
| 2023 Q2 | 830.00 AUD | -92.64% |
| 2022 Q4 | 752.00 AUD | -99.86% |
| 2022 FY | 4124.00 AUD | -99.02% |
| 2022 Q3 | 539.91 Thousand AUD | 15911.68% |
| 2022 Q2 | 3372.00 AUD | 91.48% |
| 2022 Q1 | 1761.00 AUD | -99.17% |
| 2021 Q1 | - AUD | 0.0% |
| 2021 FY | 422 Thousand AUD | -17.09% |
| 2021 Q4 | 211 Thousand AUD | 0.0% |
| 2021 Q3 | 211 Thousand AUD | 0.0% |
| 2021 Q2 | - AUD | 0.0% |
| 2020 FY | 508.97 Thousand AUD | 0.0% |
| 2019 FY | - AUD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Mayne Pharma Group Limited | 388.15 Million AUD | 99.996% |